Zelmac Cost Analysis Data Could Define Use - Committee Member
Executive Summary
Maintenance studies for Novartis' Zelmac should include a cost analysis component, FDA Gastrointestinal Drugs Advisory Committee member Michael Wolfe, MD, said June 26.
You may also be interested in...
Novartis Zelmac Dosing Instructions Among Remaining Issues In FDA Review
FDA will have to decide between a high dose or titrated regimen for Novartis' irritable bowel syndrome therapy Zelmac following a review by the Gastrointestinal Drugs Advisory Committee.
Glaxo Lotronex Formulary Kit Faulted For Implied Claims Beyond Studies
Glaxo Wellcome Lotronex marketing materials "contain unsubstantiated Health-Related Quality of Life, productivity and economic claims" not adequately supported by clinical studies, FDA charged in an April 28 letter from the agency's Division of Drug Marketing, Advertising & Communications.
Glaxo Lotronex Indication Would Cover One-Third Of IBS Patients
The recommended indication for Glaxo Wellcome's irritable bowel syndrome therapy Lotronex would cover about one-third of the U.S. IBS population.